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Prostate cancer is the most common type of solid tumor and a leading cause of cancer-related death of 
men living in the developed world. In recent years, the molecular mechanisms involved in prostate 
cancer development and/or progression have been intensely studied and several genes have been 
identified. TGIFLX/Y (TGIFLX and TGIFLY) are members of the homeobox superfamily of genes 
whose function(s) is unknown. To investigate TGIFLX/YmRNA expression in prostate cancer, we 
studied two different types of clinical samples, namely 60 prostate tumors and 15 cases of benign 
prostate hyperplasia (BPH), by RT-PCR. Our results revealed that most prostate tumors (73.5%) 
express at least one of these genes, although different patterns of TGIFLX/Y mRNA expression were 
observed. In some tumor samples the expression of both genes was detected, while in others no 
expression of either gene was observed. Notably, there was a significant correlation between 
expression of both TGIFLX and TGIFLY and a Gleason score of ≥6 (P = 0.038). By contrast, 
expression of TGIFLX/Y mRNA in BPH samples could not be detected. These results suggest an 
association of TGIFLX/Y expression with the progression of prostate cancer. 
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Introduction 
Prostate cancer (PCa) is the most frequently diagnosed non-cutaneous malignancy and the second 
leading cause of cancer death of men living in the developed world [1]. Despite the identification of 
several genes that are important in PCa development, the molecular mechanisms that contribute to the 
onset or progression of PCa are not fully understood. One group of genes implicated in PCa are the 
homeobox genes, which encode transcription factors involved in the regulation of gene expression 
[2, 3, 4], that function in normal and abnormal developmental processes [5, 6, 7]. They are 
categorized into six distinctive groups, one of which is the TALE (three amino acid loop extension) 
class. Like other homeobox classes, TALE proteins possess a helix-turn-helix DNA binding motif 
known as the homeodomain and act to regulate various cellular processes by specifically binding to 
the transcriptional control regions of target genes [8, 9, 10]. 
TGIF (TG-interacting factor) is a TALE-class homeodomain protein that serves as a multifunctional 
repressor of TGF beta-induced transcription. The related TGIF2 shows distinct homology with TGIF 
and is ubiquitously expressed in human tissues, with the highest levels being found in heart, kidney, 
and testis as well as in ovarian cancer cells [11, 12]. TGIF-like homeodomain proteins are those that 
have homology with TGIF. TGIFLX/Y is a homeobox locus related to the TALE superclass gene 
family and consists of two genes: TGIFLX (X-linked) and TGIFLY (Y-linked). TGIFLX, which is 
thought to have originated from the retrotransposition of TGIF2 [reference], is 2808 bp in length and 
comprises two exons, with the coding region being located within exon 2. In spite of the fact 
that TGIFLY shows a remarkable similarity to TGIFLX, a single nucleotide deletion in codon 149 
of TGIFLYproduces a frameshift that leads to a truncated protein (56 amino acids shorter than 
TGIFLX). The biological roles of TGIFLX/Y remain poorly understood, although both these genes are 
specifically expressed in human adult testis [13]. Consistent with this, we recently reported an 
association of TGIFLX/Y mRNA expression with azoospermia in infertile men [14]. An accumulating 
body of data also suggests a possible involvement of this class of homeobox gene in malignant 
transformation. In the present study, therefore, we investigated whether the expression 
of TGIFLX and TGIFLY may be associated with human PCa. We utilized the RT-PCR technique to 
examine TGIFLX and TGIFLY mRNA expression in both PCa and benign prostatic hyperplasia 
(BPH). 
 
Materials and methods 
Subjects 
The study group consisted of 60 previously untreated PCa patients with known histological 
information and 15 age-matched patients with untreated BPH. Indication for PCa and BPH was 
elevated serum levels of prostate-specific antigen (PSA), and further diagnosis was made by 
transrectal ultrasound (TRUS)-guided biopsies. Pathological examination confirmed the presence of 
cancerous cells or benign hyperplasias. For all patients, relevant clinical and pathological data were 
collected. 
Tissue collection and RNA extraction 
Tissue samples from patients were collected at Imam Khomeini Hospital and Bistoon Ultrasound 
Clinic, immediately placed in liquid nitrogen and carried to the laboratory for either total RNA 
isolation or storage at −70°C. Informed consent was obtained from all the participants in this study. 
During serial slide preparation samples were homogenized according to the microscopic 
characteristics of cancerous cells with more than 80% of cells that underwent RNA extraction. Tripure 
isolation reagent (Roche, Mannheim, Germany) was used for extraction of total RNA according to the 
manufacturer’s instructions with minor modifications. Briefly, the tumor specimen was homogenized 
in Tripure reagent, mixed with chloroform, then shaken vigorously for 15 s and centrifuged at 
12,000g for 15 min at 4°C. The RNA present in the upper colorless aqueous phase was precipitated by 
addition of isopropanol, washed with 75% ethanol, air-dried, and then dissolved in RNase-free water. 
Following incubation for 10 min at 55°C to allow for complete dissolution, the RNA was stored at 
−70°C. 
cDNA synthesis and RT-PCR 
For the synthesis of cDNA 1 μg of total RNA was added to a master mix that included 4 μl of 5× 
reverse transcriptase (RT) buffer (Fermentas, Burlington, Canada) 10 mM of each dNTP, 20 pmol/μl 
random primer, 20 U RNase inhibitor (Roche, Mannheim, Germany), 200 U Moloney Murine 
Leukemia Virus (M-MuLV) RT (RevertAidTM, Fermentas, Burlington, Canada), and 4 μl of DEPC-
treated water. The RT reaction was performed at 42°C for 60 min, followed by heat inactivation at 
70°C for 10 min. The integrity of cDNA was checked using the housekeeping gene 
phosphoglucomutase 1 (PGM1) primers, which amplify the region 1718–2104 (from exon 10 to exon 
11). The sequences of the used forward and reverse primers are: PGMF: 5′-
GCCCGCAGGTCCTCTTTCCCTCACA-3′ and PGMR 5′-
TCCGACTGAGCGGCACTGGGAGTGC-3′. Samples with satisfactory cDNA quality as judged by 
the PGM1 PCR were stored at −20°C for subsequent investigation. Differential expression 
of TGIFLX and TGIFLY in PCa tissues was carried out by amplification refractory mutation system 
RT-PCR. Briefly, a specific common forward primer corresponding to the 5′ untranslated region of 
both the TGIFLX and TGIFLY transcribed sequences (5′-TCGAAACAACAGTAACGATAAGCCT-
3′) was used with gene-specific reverse primers 5′-CATTGATAAACCAGTTAGAAATCT-3′ 
for TGIFLX and to 5′-CATTGATAAACCAGTTAGAAATCC-3′ for TGIFLY. Thermocycling was 
performed using a Touch-down amplification program on an ABI thermocycler. The PCR conditions 
included an initial denaturation step for 3 min at 95°C, 30 s at 95°C, 45 s at 64°C with a 1°C decrease 
every second cycle down to 55°C, then 55°C for 14 cycles, 1 min at 72°C for extension, and finally 
10 min at 72°C. PCR products were separated on 2% agarose gels and visualized with ethidium 
bromide. Positive controls for all RT-PCR assays were carried out using PGM1 and the specificity 
of TGIFLX/Y primers was tested using genomic DNA (gDNA). 
Statistical analysis 
Microsoft Excel spreadsheet and the Statistical Package for Social Sciences (SPSS) version 11.2 were 
used for data entry and analysis. Correlations between TGIFLX/Y mRNA expression and Gleason 




TGIFLX/Y mRNA expression in prostate cancer and BPH biopsy 
Sixty PCa patient’s, relevant clinical and pathological data were collected and showed that 13.4%, 
58.3%, and 28.3% of prostate cancer patients represented Gleason scores with (4–5), (6–7), and (8–
10), respectively. To examine the expression of TGIFLX and TGIFLY in human PCa, total RNA was 
obtained from 60 PCa tumors as well as 15 BPH specimens. The principal characteristics of these 
study populations are presented in Table 1. In the first instance, we confirmed RNA quality by RT-
PCR for PGM1 gene expression and representative results of four PCa tumors are shown in Fig. 1. A 
survey of TGIFLX and TGIFLY expression revealed that, whereas most PCa specimens (73.5%) 
contained transcripts from at least one of these genes (Table 2, Fig. 2), neither gene was expressed in 
cases of BPH (data not shown). 
The expression of TGIFLX and TGIFLY showed different patterns among the various PCa patients 
(Table 2). TGIFLY was expressed in 36 out of 60 (60%) and TGIFLX expression in 31 out of 60 
(51.6%) cases. When the expression of both genes was analyzed, 38.3% patients were positive for 
both genes, 21.6% had only TGIFLY expression and were negative for TGIFLXgene, 13.3% 
showed TGIFLX expression only, and 26.6% had no expression of either gene. 
Expression of TGIFLX/Y is associated with higher-grade prostate cancer 
We analyzed the correlation between TGIFLX/Y gene expression and Gleason score in the PCa 
specimens by SPSS and Fisher’s exact test for each of the genes (Table 3). In samples in which one, 
or both, of these genes were expressed (TGIFLX+/Y+, TGIFLX+/Y−, TGIFLX−/Y+), a significant 
association between their expression and a Gleason score of ≥6 was observed (P = 0.038). By 
contrast, TGIFLX/Y gene expression did not show any significant correlation with PSA level, patient 
age, or prostate size. 
 
Discussion 
Several studies have demonstrated that heterogeneity increases markedly with progression from 
benign prostate hyperplasia through prostatic intraepithelial neoplasia (PIN) to localized PCa and 
metastases [15]. By using a genome-wide scan, several candidate genes have been identified for 
malignant transformation in the prostate [16, 17, 18]. 
In a previous gene expression study, we identified an association between human 
homeobox TGIFLX/Y mRNA expression with azoospermia in men [14]. The TGIFLX/Y gene is a 
member of TALE group of homeobox genes, which is specifically expressed in human adult testis 
[13]. In male infertility, TGIFLX/Y has been implicated in the azoospermia phenotype [14]. The 
results of the present work show a significant correlation between TGIFLX/Y gene expression and 
Gleason score in prostate cancer. The TGIFLX/Y gene is not the first homeobox gene to be implicated 
in the development of prostate cancer. Aberrant HOXC8 expression was reported in human prostate 
tumors where it was associated with loss of differentiation [19]. Subsequently, Miller et al. [20] found 
overexpression of four HOXC cluster genes (HOXC4, HOXC5, HOXC6, and HOXC8) in malignant 
prostate cell lines and lymph node metastases using RT-PCR. By RT-PCR, we detected the 
expression of both TGIFLX and TGIFLY in 23 out of 60 (38.3%) prostate tumors, but not in BPH 
samples. This dysregulation points to a possible involvement of TGIFLX/Y expression with 
malignancy in prostate cells. 
The expression patterns of HOX genes, which are normally expressed in proliferating and/or 
differentiated tissues, are often different in comparison to cancerous cells [17, 21]. This reflects the 
now well established view that HOX genes can play a role in the process of carcinogenesis by acting 
in different pathways [22, 23]. In several cancers, HOX genes function by either gain or loss of 
expression, which is associated with their oncogene-like or tumor suppressor-like activities, 
respectively. The loss-of-function of the NKX3.1 homeobox gene is an important example of the latter 
in respect to prostate cancer. Since TGIFLX/Y gene expression is normally lacking in the prostate, its 
presence can be categorized as a “gain” of expression in prostate cancer. Although different patterns 
of TGIFLX/Y mRNA expression in PCa biopsies could be due to genetic heterogeneity, our results 
suggest that TGIFLX/Y may have a role in cancer development, especially since mRNA expression 
of TGIFLX and TGIFLYwere not detected among BPH samples. 
Significantly, expression of TGIFLX/Y genes was associated with a Gleason score of ≥6. Other genes 
whose aberrant expression have been reported to be associated with a higher Gleason score in prostate 
cancer include HOXC8 [19], E-cadherin [17, 24], and DNp73 [25], a p53 homologue that induces 
apoptosis and inhibits cell proliferation in benign and malignant tumors of the prostate. Our results 
suggest interactive effects between the TGIFLX and TGIFLY genes in prostate cancer progression. 
However, it is also possible that TGIFLX and TGIFLY act as redundant regulatory proteins, at least in 
the context of their abnormal function in tumor development. Several studies have reported 
redundancy between some homeobox genes [26, 27, 28]. The best examples to date are two nearly 
identical homeobox genes of the TGIF subclass, vismay and achinta (vis/achi), in Drosophila 
melanogaster that are normally expressed in the testes. Wang and Mann [28] indicated that Vis and 
Achi are redundant transcriptional regulators that function at the same step in normal sperm 
development. Thus, it remains a possibility that expression of either the TGIFLX or TGIFLYgenes 
could have a role malignancy. 
In conclusion, our results indicate a significant correlation between prostate cancer and the abnormal 
expression of the TGIFLX and TGIFLY genes. Nevertheless, the precise mechanisms by which these 
genes are involved in tumorigenesis remain to be elucidated. The use of specific antibodies for precise 
quantification and localization, together with measurement of interaction with other proteins, will be a 
first step in addressing the direct or indirect involvement of the TGIFLX/Y genes in normal and 
abnormal biological functions. 
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Characteristics   Cancer patients (n) BPH patients (n) 
Age (years) Mean (95% 
CI) 
69.2(67–71) 64.5(62.9–66.1) 
Minimum 48 46 
Maximum 85 82 
PSA (ng/ml) Mean (95% 
CI) 
20.7(13.5–27.8) 12.7(9.32–16.18) 
Minimum 1.2 0.8 






Minimum 17 26 
Maximum 153 156 
Gleason score Mean (95% 
CI) 
6.9(6.5–7.3) – 
Minimum 4 – 






Table 2 Expression of TGIFLX and TGIFLY genes in prostate cancers 
 
 
Expression pattern of TGIFLX (X) and TGIFLY (Y) Number Percentage (%) 
X+ Y+ 23 39 
X+ Y− 8 13 
X− Y+ 13 21.5 
X− Y− 16 26.5 


























  Gleason score 
4–5 (%) 6–7 (%) 8–10 (%) 
X+ Y+ 0 25.92 11.11 
X+ Y− 0 11.11 0 
X− Y+ 3.70 7.40 11.11 





















Fig. 1 Confirmation of RNA quality by RT-PCR of the PGM1 housekeeping control gene. Shown are 
representative RT-PCR products resolved on a 2% agarose gel stained with ethidium bromide. Lanes 
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